Lv5
850 积分 2021-03-22 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
21天前
已完结
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
23天前
已完结
AI-based augmentation of oncology clinical trials
1个月前
已完结
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
1个月前
已完结
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
2个月前
已完结
Imaging the hallmarks of cancer
2个月前
已完结
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study
4个月前
已完结
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
4个月前
已完结
Ivonescimab in advanced squamous non-small-cell lung cancer: can we raise the survival bar?
4个月前
已完结
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
4个月前
已完结
皖公网安备34019202002308
